266 related articles for article (PubMed ID: 31296355)
1. Stopping oral steroid-sparing agents at initiation of rituximab in myasthenia gravis.
Roda RH; Doherty L; Corse AM
Neuromuscul Disord; 2019 Jul; 29(7):554-561. PubMed ID: 31296355
[TBL] [Abstract][Full Text] [Related]
2. Rituximab as treatment for anti-MuSK myasthenia gravis: Multicenter blinded prospective review.
Hehir MK; Hobson-Webb LD; Benatar M; Barnett C; Silvestri NJ; Howard JF; Howard D; Visser A; Crum BA; Nowak R; Beekman R; Kumar A; Ruzhansky K; Chen IA; Pulley MT; LaBoy SM; Fellman MA; Greene SM; Pasnoor M; Burns TM
Neurology; 2017 Sep; 89(10):1069-1077. PubMed ID: 28801338
[TBL] [Abstract][Full Text] [Related]
3. Rituximab in the management of refractory myasthenia gravis.
Zebardast N; Patwa HS; Novella SP; Goldstein JM
Muscle Nerve; 2010 Mar; 41(3):375-8. PubMed ID: 19852027
[TBL] [Abstract][Full Text] [Related]
4. Long-Lasting Rituximab-Induced Reduction of Specific-But Not Total-IgG4 in MuSK-Positive Myasthenia Gravis.
Marino M; Basile U; Spagni G; Napodano C; Iorio R; Gulli F; Todi L; Provenzano C; Bartoccioni E; Evoli A
Front Immunol; 2020; 11():613. PubMed ID: 32431692
[TBL] [Abstract][Full Text] [Related]
5. Rituximab treatment of myasthenia gravis: A systematic review.
Tandan R; Hehir MK; Waheed W; Howard DB
Muscle Nerve; 2017 Aug; 56(2):185-196. PubMed ID: 28164324
[TBL] [Abstract][Full Text] [Related]
6. High efficacy of rituximab for myasthenia gravis: a comprehensive nationwide study in Austria.
Topakian R; Zimprich F; Iglseder S; Embacher N; Guger M; Stieglbauer K; Langenscheidt D; Rath J; Quasthoff S; Simschitz P; Wanschitz J; Windisch D; Müller P; Oel D; Schustereder G; Einsiedler S; Eggers C; Löscher W
J Neurol; 2019 Mar; 266(3):699-706. PubMed ID: 30649616
[TBL] [Abstract][Full Text] [Related]
7. Development of generalized disease at 2 years in patients with ocular myasthenia gravis.
Kupersmith MJ; Latkany R; Homel P
Arch Neurol; 2003 Feb; 60(2):243-8. PubMed ID: 12580710
[TBL] [Abstract][Full Text] [Related]
8. Successful treatment of MuSK antibody-positive myasthenia gravis with rituximab.
Hain B; Jordan K; Deschauer M; Zierz S
Muscle Nerve; 2006 Apr; 33(4):575-80. PubMed ID: 16323216
[TBL] [Abstract][Full Text] [Related]
9. Longstanding and Refractory Anti-Muscle Specific Tyrosine Kinase Antibody-Associated Myasthenia Gravis (Anti-MuSK-MG) in a Child Successfully Treated with Rituximab.
Weger S; Appendino JP; Clark IH
J Binocul Vis Ocul Motil; 2019; 69(1):26-29. PubMed ID: 30811277
[TBL] [Abstract][Full Text] [Related]
10. Thymectomy may not be associated with clinical improvement in MuSK myasthenia gravis.
Clifford KM; Hobson-Webb LD; Benatar M; Burns TM; Barnett C; Silvestri NJ; Howard JF; Visser A; Crum BA; Nowak R; Beekman R; Kumar A; Ruzhansky K; Chen IA; Pulley MT; Laboy SM; Fellman MA; Howard DB; Kolb NA; Greene SM; Pasnoor M; Dimachkie MM; Barohn RJ; Hehir MK
Muscle Nerve; 2019 Apr; 59(4):404-410. PubMed ID: 30575980
[TBL] [Abstract][Full Text] [Related]
11. Short-term effect of low-dose rituximab on myasthenia gravis with muscle-specific tyrosine kinase antibody.
Zhou Y; Yan C; Gu X; Zhou L; Lu J; Zhu W; Huan X; Luo S; Zhong H; Lin J; Lu J; Zhao C; Xi J
Muscle Nerve; 2021 Jun; 63(6):824-830. PubMed ID: 33745138
[TBL] [Abstract][Full Text] [Related]
12. Rituximab as a sole steroid-sparing agent in generalized myasthenia gravis: Long-term outcomes.
Kefalopoulou ZM; Veltsista D; Germeni A; Lykouras D; Tsiamaki E; Chroni E
Neurol Sci; 2024 Mar; 45(3):1233-1242. PubMed ID: 37831214
[TBL] [Abstract][Full Text] [Related]
13. Rituximab in AChR subtype of myasthenia gravis: systematic review.
Di Stefano V; Lupica A; Rispoli MG; Di Muzio A; Brighina F; Rodolico C
J Neurol Neurosurg Psychiatry; 2020 Apr; 91(4):392-395. PubMed ID: 32098874
[TBL] [Abstract][Full Text] [Related]
14. Refractory myasthenia gravis - clinical profile, comorbidities and response to rituximab.
Sudulagunta SR; Sepehrar M; Sodalagunta MB; Settikere Nataraju A; Bangalore Raja SK; Sathyanarayana D; Gummadi S; Burra HK
Ger Med Sci; 2016; 14():Doc12. PubMed ID: 27790079
[No Abstract] [Full Text] [Related]
15. Selective response to rituximab in a young child with MuSK-associated myasthenia gravis.
Govindarajan R; Iyadurai SJ; Connolly A; Zaidman C
Neuromuscul Disord; 2015 Aug; 25(8):651-2. PubMed ID: 25998611
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of rituximab in myasthenia gravis: a French multicentre real-life study.
Dos Santos A; Noury JB; Genestet S; Nadaj-Pakleza A; Cassereau J; Baron C; Videt D; Michel L; Pereon Y; Wiertlewski S; Magot A
Eur J Neurol; 2020 Nov; 27(11):2277-2285. PubMed ID: 32526053
[TBL] [Abstract][Full Text] [Related]
17. Autoantibody-producing plasmablasts after B cell depletion identified in muscle-specific kinase myasthenia gravis.
Stathopoulos P; Kumar A; Nowak RJ; O'Connor KC
JCI Insight; 2017 Sep; 2(17):. PubMed ID: 28878127
[TBL] [Abstract][Full Text] [Related]
18. Differential response to rituximab in anti-AChR and anti-MuSK positive myasthenia gravis patients: a single-center retrospective study.
Litchman T; Roy B; Kumar A; Sharma A; Njike V; Nowak RJ
J Neurol Sci; 2020 Apr; 411():116690. PubMed ID: 32028072
[TBL] [Abstract][Full Text] [Related]
19. Rituximab as Adjunct Maintenance Therapy for Refractory Juvenile Myasthenia Gravis.
Zingariello CD; Elder ME; Kang PB
Pediatr Neurol; 2020 Oct; 111():40-43. PubMed ID: 32951658
[TBL] [Abstract][Full Text] [Related]
20. Association between musk antibody concentrations and the myasthenia gravis composite score in 3 patients: A marker of relapse?
Triplett JD; Hardy TA; Riminton DS; Chu SYK; Reddel SW
Muscle Nerve; 2019 Sep; 60(3):307-311. PubMed ID: 31177576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]